GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ORGO · Jun 30, 2025

Organogenesis Holdings Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0000950170-25-105048General Corporate

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

3.60% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-32.55% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

-22.44% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

32.71% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-12.45% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

10.29% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

2.52% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building

Dec 31, 20230/8 normalizedLevel 3 Mar 31, 20240/8 normalizedLevel 3 Jun 30, 20240/8 normalizedLevel 3 Sep 30, 20240/8 normalizedLevel 3 Dec 31, 20240/8 normalizedLevel 3 Mar 31, 20250/8 normalizedLevel 3 Jun 30, 20250/7 normalizedLevel 3 Sep 30, 20250/7 normalizedLevel 3 Dec 31, 20256/7 normalizedLevel 3 Mar 31, 20266/7 normalizedLevel 3 Jun 30, 20266/7 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Decreased

Previous: 4.18%
Current: 3.60%
Delta: -0.58%

Cash Generation Decreased

Previous: -22.99%
Current: -32.55%
Delta: -9.55%

Growth Decreased

Previous: -21.17%
Current: -22.44%
Delta: -1.27%

Inventory Pressure Decreased

Previous: 33.84%
Current: 32.71%
Delta: -1.13%

Profitability Increased

Previous: -30.85%
Current: -12.45%
Delta: 18.40%

R And D Intensity Decreased

Previous: 12.27%
Current: 10.29%
Delta: -1.98%

Sbc Intensity Decreased

Previous: 3.88%
Current: 2.52%
Delta: -1.37%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · ORGO Fundamental State →Has State · Organogenesis Holdings Inc. →Transitioned To · ORGO Fundamental State →Transitioned To · ORGO CAPEX_INTENSITY_DECREASED →Transitioned To · ORGO CASH_GENERATION_DECREASED →Transitioned To · ORGO GROWTH_DECREASED →Transitioned To · ORGO INVENTORY_PRESSURE_DECREASED →Transitioned To · ORGO PROFITABILITY_INCREASED →Transitioned To · ORGO R_AND_D_INTENSITY_DECREASED →Transitioned To · ORGO SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.